Evidence map›Paper›PMID 33772723›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Propofol inhibited gastric cancer proliferation via the hsa-miR-328-3p/STAT3 pathway.

Z M Bai, X F Li, Y Yang, Y F Yang, D R Lv, L L Tang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Does anesthesia choice shape oncologic destiny in gastric cancer surgery?World journal of gastrointestinal oncology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Z M BaiDepartment of Anesthesiology, Wuwei People's Hospital, North Side of Xuanwu Street, Liangzhou District, Wuwei, 733000, China.
X F LiDepartment of Neonatology, Wuwei People's Hospital, Wuwei, 733000, China.
Y YangDepartment of Chinese Medicine, Rheumatology and Immunology, Wuwei Liangzhou Hospital, Wuwei, 733000, China.
Y F YangDepartment of Neurocardiology, Wuwei Second People's Hospital, Wuwei, 733000, China.
D R LvDepartment of Anesthesiology, Wuwei People's Hospital, North Side of Xuanwu Street, Liangzhou District, Wuwei, 733000, China.
L L TangDepartment of Anesthesiology, Wuwei People's Hospital, North Side of Xuanwu Street, Liangzhou District, Wuwei, 733000, China. laatq9@163.com.ORCID http://orcid.org/0000-0002-1478-901X
Huawei Technologies (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the present study was to elucidate the functional role of hsa-miR-328-3p/STAT3 pathway in the effects of propofol on gastric cancer proliferation.

methodsBioinformatics was used to analyze the molecular expression differences of hsa-miR-328-3p/STAT3 axis in stomach adenocarcinoma (n = 435) and normal samples (n = 41) from TCGA database. The expression of the above molecules in gastric cancer cells SGC-7901 and normal gastric mucosal cells GES-1 was verified via qPCR. The dual-luciferase assay was carried out to confirm the interaction between hsa-miR-328-3p and STAT3. Subsequently, the cell proliferation and the expression of the above molecules in SGC-7901 and GES-1 cells were evaluated after 10 μM propofol treatment. Finally, we analyzed whether propofol still inhibited the proliferation of gastric cancer by suppressing STAT3 pathway after hsa-miR-328-3p down-regulation.

resultsCompared with normal samples, the expression of hsa-miR-328-3p was significantly down-regulated in stomach adenocarcinoma samples, while the expression of STAT3 and downstream target genes (MMP2, CCND1 and COX2) was up-regulated. The results were consistent with those in GES-1 and SGC-7901 cell lines. Meanwhile, we found that hsa-miR-328-3p can bind to the 3'-UTR of the potential target gene STAT3. Furthermore, propofol significantly inhibited the proliferation of gastric cancer cell line SGC-7901, where hsa-miR-328-3p was up-regulated and the expression of STAT3 and downstream proliferation-related target genes were down-regulated. However, the growth inhibition of propofol on SGC-7901 cell was significantly reversed after the inhibition of hsa-miR-328-3p.

conclusionsTo sum up, propofol suppressed the STAT3 pathway via up-regulating hsa-miR-328-3p to inhibit gastric cancer proliferation.

Indexed as

3' Untranslated RegionsAdenocarcinomaAnesthetics, IntravenousCell Line, TumorCell ProliferationComputational BiologyCyclin D1Cyclooxygenase 2Down-RegulationGastric MucosaHumansLuciferasesMatrix Metalloproteinase 2MicroRNAsPropofolSTAT3 Transcription Factor3' Untranslated RegionsAnesthetics, IntravenousCCND1 protein, humanCyclin D1Cyclooxygenase 2LuciferasesMatrix Metalloproteinase 2MicroRNAsMIRN328 microRNA, humanMMP2 protein, humanPropofolSTAT3 protein, humanSTAT3 Transcription FactorGastric cancerhas-miR-328-3pProliferationPropofolSTAT3

Identifiers

PMID33772723
OpenAlexW3140620995

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.